Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. METHODS: We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-19, within 24...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953461/
https://www.ncbi.nlm.nih.gov/pubmed/33631065
http://dx.doi.org/10.1056/NEJMoa2100433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953461/
https://www.ncbi.nlm.nih.gov/pubmed/33631065
http://dx.doi.org/10.1056/NEJMoa2100433

Ejemplares similares